No­vo Nordisk picks up sick­le-cell dis­ease drug in $400M li­cens­ing pact; Sapi­ence teams up with UK re­searcher on ...

8 years ago
News Briefing

Evo­lus touts equal ef­fi­ca­cy for its Botox me-too drug in PhI­II Eu­ro­pean/Cana­di­an tri­als

8 years ago
R&D

Fer­ring buys up PhI­II mi­cro­bio­me drug with ac­qui­si­tion of Re­bi­otix

8 years ago
Deals

EMA hands Italy's Chiesi a win in its long cam­paign to ad­vance new drugs for rare dis­eases

8 years ago
Pharma

$21B or bust! Ab­b­Vie en­sures its block­buster US marathon on Hu­mi­ra will run in­to 2023

8 years ago
Pharma

RA Cap­i­tal jumps in­to the melee on TTR amy­loi­do­sis, back­ing a $91M de­vel­op­ment plan for a Bridge­Bio drug

8 years ago
Financing

No­var­tis-backed Cona­tus high­lights a sil­ver lin­ing, but PhI­Ib NASH-re­lat­ed set­back caus­es whiplash in share price

8 years ago
R&D

Har­vard big-shots Kevin Eggan and Clif­ford Woolf launch ALS start­up with ex­clu­sive Q-State tech

8 years ago
Startups

Boehringer In­gel­heim is think­ing in block­buster terms as it throws its hat in­to the ever-widen­ing CD47 ring

8 years ago
R&D
Pharma

CAR-T play­er Po­sei­da march­es on with $30.5M Se­ries B; Kymera inks dis­cov­ery deal with GSK

8 years ago
News Briefing

Biotech gains ground in NYC: Sprawl­ing re­search cen­ter planned in $1.6B Mid­town project

8 years ago
Pharma

Rid­ing a wave of pos­i­tive PhI­II read­outs, Pfiz­er gets a snap re­view for lung can­cer drug da­comi­tinib

8 years ago
Pharma

In­sti­tu­tion­al re­search is flawed. I'm team­ing with End­points to help de­moc­ra­tize it

8 years ago
Publisher's note
Pharma

On the heels of ma­jor Pfiz­er deal, Arv­inas snags $55M Se­ries C for pro­tein degra­da­tion can­cer pro­grams

8 years ago
Financing

Roche grabs a re­myeli­na­tion MS drug from Ver­sant as the re­search team spins out in­to a $25M re­gen­er­a­tive med start­up

8 years ago
Startups
Pharma

Eli Lil­ly jumps in­to a $473M hunt with Sig­ilon for the Holy Grail in di­a­betes cell ther­a­pies

8 years ago
R&D
Pharma

With $340M crossover fund, Sofinno­va Part­ners piv­ots to late-stage biotech in­vest­ments while main­tain­ing Eu­ro­pean ...

8 years ago
Financing

Eli Lil­ly hands transpa­cif­ic biotech up­start Terns pieces to an ex­per­i­men­tal NASH puz­zle

8 years ago
Startups
Pharma

A gene ther­a­py mys­tery? Gen­Sight blast­ed as 1st PhI­II eye study ends in an in­trigu­ing fail­ure

8 years ago
R&D
Cell/Gene Tx

As­traZeneca wins pri­or­i­ty re­view sched­ule for leukemia drug; Penn gene ther­a­py up­start grabs $9.29M with Fra­zier's ...

8 years ago
News Briefing

Al­ler­gan, Richter prep for FDA OK with pos­i­tive PhI­II for cariprazine in bipo­lar de­pres­sion

8 years ago
R&D

Bellde­grun teams with a group of top VC play­ers to un­veil a $295M biotech fund at Vi­da Ven­tures

8 years ago
Financing

Arie Bellde­grun rais­es $300M, grabs Pfiz­er’s al­lo­gene­ic CAR-T port­fo­lio and launch­es a ground­break­ing dri­ve to ...

8 years ago
Financing
Startups

Rigel hit with an­oth­er tri­al set­back as lead drug fos­ta­ma­tinib fails PhII

8 years ago
R&D
First page Previous page 1038103910401041104210431044 Next page Last page
A service from the Financial Times